9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis

Pathology International

Volumn 60, Issue 5, 2010, Pages 395-399

  Takeda, Maiko ^a   Kasai, Takahiko ^a   Enomoto, Yasunori ^a   Takano, Masato ^a   Morita, Kouhei ^a   Kadota, Eiji ^b   Nonomura, Akitaka ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

9p21; FISH; Immunohistochemistry; Mesothelioma; P16

Indexed keywords

ONCOPROTEIN; PROTEIN 9P21; PROTEIN P16; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; GENETIC ANALYSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CHROMOSOMES, HUMAN, PAIR 9; DNA, NEOPLASM; EPITHELIUM; FEMALE; GENE DELETION; GENE DOSAGE; GENES, P16; HEART NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MESOTHELIOMA; PERICARDIUM; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951919594     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02534.x     Document Type: Article

References (23)

1. Peto J, Hodgson JT, Matthews FE et al. Continuing increase in mesothelioma mortality in British. Lancet 1995 345 : 535 539.
2. Statistics and Information Department. Labour and Welfare of Japan. Vital Statistics of Japan 2004.
3. Churg A, Roggli V, Galateau-Salle F et al. Tumours of the pleura: Mesothelial tumours. In : Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, eds. World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart.
4. Churg A, Cagle PT, Roggli VL. Tumor of the Serosal Membranes. Atlas of Tumor Pathology Fascicle.
5. US-Canadian Mesothelioma Reference Panel : Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelialproliferations. Am J Surg Pathol 2000 24 : 1183 1200.
6. Allen TG. Recognization of histopathologicpatterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med 2005 129 : 1415 1420.
7. Yaziji H, Battifora H, Barry TS et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006 19 : 514 523.
8. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 2005 129 : 1421 1427.
9. Churg A, Colvy TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000 24 : 1183 1200.
10. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002 29 : 2 17.
11. Musti M, Kettunen E, Dragonieri S et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006 170 : 9 15.
12. Illei PB, Rusch VR, Zakowski MF et al. Homozygous deletion of CDKN2A and correlation of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003 9 : 2108 2113.
13. Singhal S, Wiewrodt R, Malden LD et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003 9 : 3080 3097.
14. Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and p16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006 66 : 2970 2979.
15. Chinosea S, Krasinskas A, Cagle PT et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesithliomas. Mod Pathol 2008 21 : 242 247.
16. Walts AE, Lechago J, Bose S. P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. Am J Surg Pathol 2006 30 : 795 801.
17. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Böcking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008 114 : 204 215.
18. Xio S, Li D, Vijg J et al. Co-deletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995 11 : 511 515.
19. Cheng JQ, Jhanwar SC, Klein WM et al. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994 54 : 5547 5551.
20. Prins JB, Williamson KA, Kamp MM et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998 75 : 649 653.
21. Illei PB, Ladanyi M, Rusch VW et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003 99 : 51 6.
22. Testa JR, Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol 2001 11 : 31.
23. Hirao T, Bueno R, Chen C-J et al. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002 23 : 1127 1130.